RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.
- glycine transporter-1 inhibitor
- negative symptoms
ASJC Scopus subject areas
- Cognitive Neuroscience
- Cell Biology